- Home
- LU vs IRON Comparison
LU vs IRON Comparison
Compare LU & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LU
- IRON
- Stock Information
- Founded
- LU 2005
- IRON 2017
- Country
- LU China
- IRON United States
- Employees
- LU N/A
- IRON N/A
- Industry
- LU Finance: Consumer Services
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- LU Finance
- IRON Health Care
- Exchange
- LU Nasdaq
- IRON Nasdaq
- Market Cap
- LU 2.4B
- IRON 1.9B
- IPO Year
- LU 2020
- IRON N/A
- Fundamental
- Price
- LU $3.10
- IRON $54.53
- Analyst Decision
- LU Hold
- IRON Strong Buy
- Analyst Count
- LU 2
- IRON 10
- Target Price
- LU $2.98
- IRON $74.40
- AVG Volume (30 Days)
- LU 4.0M
- IRON 329.3K
- Earning Date
- LU 03-20-2025
- IRON 03-20-2025
- Dividend Yield
- LU 76.33%
- IRON N/A
- EPS Growth
- LU N/A
- IRON N/A
- EPS
- LU N/A
- IRON N/A
- Revenue
- LU $4,671,260,668.00
- IRON N/A
- Revenue This Year
- LU N/A
- IRON N/A
- Revenue Next Year
- LU $1.48
- IRON N/A
- P/E Ratio
- LU N/A
- IRON N/A
- Revenue Growth
- LU N/A
- IRON N/A
- 52 Week Low
- LU $2.00
- IRON $25.60
- 52 Week High
- LU $4.94
- IRON $77.60
- Technical
- Relative Strength Index (RSI)
- LU 68.59
- IRON 41.25
- Support Level
- LU $2.78
- IRON $52.21
- Resistance Level
- LU $2.96
- IRON $55.89
- Average True Range (ATR)
- LU 0.13
- IRON 1.86
- MACD
- LU 0.06
- IRON 0.20
- Stochastic Oscillator
- LU 88.83
- IRON 48.48
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.